热门资讯> 正文

Solid Biosciences将AAV-SLB 101许可证授予Kamar Bio

2025-09-23 21:41

Solid Biosciences (NASDAQ:SLDB) has entered into a collaboration with Kinea Bio, granting them a non-exclusive worldwide license to use Solid’s AAV-SLB101 capsid.
This partnership focuses on the development and commercialization of KNA-155 using AAV-SLB101, for the treatment of dysferlinopathy, a type of limb-girdle muscular dystrophy.
Under the deal, Solid Biosciences will receive an upfront payment and may earn additional payments as Kinea Bio meets specific development and sales milestones, along with tiered royalties based on net sales.

More on Solid Biosciences

Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript
Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)
Solid Biosciences GAAP EPS of -$0.42 beats by $0.09
Solid Biosciences gets FDA fast track status for heart disease therapy
Seeking Alpha’s Quant Rating on Solid Biosciences

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。